Roche CEO Says Widespread Vaccine This Year Is Unlikely

The speaker discusses concerns about unrealistic expectations for vaccine availability, emphasizing the challenges in development, testing, and production. They stress the importance of managing public expectations to maintain trust and credibility. The speaker reassures that safety is a priority for companies and regulators, and a realistic timeline for widespread vaccine availability is the second half of next year.

What is the speaker's main concern regarding the pace of vaccine development?

• That it is too fast and unsafe

• That it is too slow and ineffective

• That expectations are set too high

• That it is not being funded enough

Why does the speaker believe it is unrealistic to expect a vaccine for everyone by the end of the year?

• Due to the lengthy process of testing and production scaling

• Because the technology is not advanced enough

• Due to lack of interest from pharmaceutical companies

• Because there is no demand for it

What does the speaker suggest is necessary to keep public support during vaccine development?

• Offering financial incentives

• Increasing media coverage

• Providing free vaccines

• Setting realistic expectations

What is the speaker's view on the role of companies and regulators in vaccine safety?

• They are not concerned about safety

• They are delaying the process unnecessarily

• They prioritize safety to ensure only safe medicines reach people

• They are only interested in profits

What is the speaker's main concern about public expectations?

• That they are ignored by the media

• That they are not communicated well

• That they are too low

• That they are too high and unrealistic